Halozyme Therapeutics

(NASDAQ) HALO

Current Price$64.52

Market Cap$7.65B

Since IPO (2004)+1,441%

5 Year+35%

1 Year+6%

1 Month+0%

Halozyme Therapeutics Financials at a Glance

Market Cap

$7.65B

Revenue (TTM)

$1.40B

Net Income (TTM)

$316.89M

EPS (TTM)

$2.49

P/E Ratio

25.91

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Price

$64.52

Volume

917,930.271

Open

$63.50

Price

$64.52

Volume

917,930.271

Open

$63.50

Previous Close

$64.57

Daily Range

$63.11 - $64.68

52-Week Range

$47.50 - $82.22

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Price

$64.52

Volume

917,930.271

Open

$63.50

Previous Close

$64.57

Daily Range

$63.11 - $64.68

52-Week Range

$47.50 - $82.22

HALO News

The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.

Josh Kohn-LindquistDec 6, 2025

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look

Josh Kohn-LindquistNov 5, 2025

Halozyme (HALO) Q2 EPS Jumps 69%

Motley Fool Markets TeamAug 5, 2025

Would Halozyme Make a Good Warren Buffett Stock?

Alex CarchidiApr 4, 2021

Are Biotech Stocks a Good Hedge Against Higher Inflation?

Alex CarchidiMar 27, 2021

Page 1

HALO: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Halozyme Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

423

CEO

Helen I. Torley, MD

Website

www.halozyme.com

Headquarters

San Diego, CA 92121, US

HALO Financials

Key Financial Metrics (TTM)

Gross Margin

82%

Operating Margin

58%

Net Income Margin

23%

Return on Equity

154%

Return on Capital

35%

Return on Assets

13%

Earnings Yield

3.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.65B

Shares Outstanding

118.47M

Volume

917.93K

Avg. Volume

1.64M

Financials (TTM)

Gross Profit

$1.09B

Operating Income

$816.29M

EBITDA

$904.34M

Operating Cash Flow

$651.56M

Capital Expenditure

$6.97M

Free Cash Flow

$644.59M

Cash & ST Invst.

$142.82M

Total Debt

$0.00

Halozyme Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$451.77M

+51.6%

Gross Profit

$349.62M

+36.6%

Gross Margin

77.39%

N/A

Market Cap

$7.65B

N/A

Market Cap/Employee

$21.86M

N/A

Employees

350

N/A

Net Income

$141.59M

-203.3%

EBITDA

$281.08M

+38.3%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$142.82M

+115.7%

Accounts Receivable

$441.27M

+43.1%

Inventory

$176.47M

+24.4%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

N/A

Return on Assets

12.55%

N/A

Return on Invested Capital

34.76%

N/A

Free Cash Flow

$217.60M

+24.0%

Operating Cash Flow

$219.03M

+22.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ABVXAbivax S.A.

ABVXAbivax S.A.$117.13-0.41%

ATRAptarGroup, Inc.

ATRAptarGroup, Inc.$120.60+1.33%

CYTKCytokinetics, Incorporated

CYTKCytokinetics, Incorporated$66.05+4.26%

HSICHenry Schein, Inc.

HSICHenry Schein, Inc.$72.02-2.58%

GRFSGrifols, S.A.

GRFSGrifols, S.A.$8.23+0.00%

MRUSMerus N.V.

MRUSMerus N.V.$90.00+0.00%

RYTMRhythm Pharmaceuticals, Inc.

RYTMRhythm Pharmaceuticals, Inc.$85.58+4.61%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

CNSPCns Pharmaceuticals

CNSPCns Pharmaceuticals$7.84+2.39%

GBTGGlobal Business Travel Group

GBTGGlobal Business Travel Group$9.34+0.58%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.18+0.01%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.69-0.00%

SOFISoFi Technologies

SOFISoFi Technologies$16.20-0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.91-0.01%

NCLHNorwegian Cruise Line

NCLHNorwegian Cruise Line$17.20-0.09%

Questions About HALO

What is the current price of Halozyme Therapeutics?

Halozyme Therapeutics is trading at $64.57 per share.

What is the 52-week range for Halozyme Therapeutics?

Over the past 52 weeks, Halozyme Therapeutics has traded between $47.50 and $82.22.

How much debt does Halozyme Therapeutics have?

As of the most recent reporting period, Halozyme Therapeutics reported total debt of $2.18B.

How much cash does Halozyme Therapeutics have on hand?

Halozyme Therapeutics reported $133.82M in cash and cash equivalents in its most recent financial results.

What is Halozyme Therapeutics’s dividend yield?

Halozyme Therapeutics does not currently have a dividend yield.

Halozyme Therapeutics

Halozyme Therapeutics Financials at a Glance

HALO News

How to Invest in iShares Russell 2000 ETF (IWM)

2 Under-the-Radar Biotech Stocks Set to Boom in 2026

Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty

The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look

Halozyme (HALO) Q2 EPS Jumps 69%

Would Halozyme Make a Good Warren Buffett Stock?

Are Biotech Stocks a Good Hedge Against Higher Inflation?

HALO: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Halozyme Therapeutics

HALO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Halozyme Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About HALO

What is the current price of Halozyme Therapeutics?

What is the 52-week range for Halozyme Therapeutics?

How much debt does Halozyme Therapeutics have?

How much cash does Halozyme Therapeutics have on hand?

What is Halozyme Therapeutics’s dividend yield?

Premium Investing Services